Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onternabez - Panag Pharma/Tetra Bio Pharma

Next Previous
Drug Profile

Onternabez - Panag Pharma/Tetra Bio Pharma

Alternative Names: ARDS-003; HU-308; PPP-003; PPP-003 Covid product - Tetra Bio-Pharma

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panag Pharma
  • Developer Panag Pharma; Tetra Bio Pharma
  • Class Alcohols; Analgesics; Anti-infectives; Anti-inflammatories; Cannabinoids; Eye disorder therapies; Small molecules; Urologics
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Proliferative vitreoretinopathy
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cytokine release syndrome; Dry eyes; Proliferative vitreoretinopathy; Renal failure; SARS-CoV-2 acute respiratory disease; Sepsis; Uveitis

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in SARS-COV-2 acute respiratory disease in Canada (IV, Injection)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Dry-eyes in Canada (Ophthalmic, Tablet)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Uveitis in Canada (Ophthalmic)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top